Neuronetics Brand Guidelines: Malvern 2003, NeuroStar TMS & the Greenbrook Clinics

A Pennsylvania company built on magnetic stimulation.

Neuronetics is a medical-technology company in Malvern, Pennsylvania, in the suburbs west of Philadelphia. Renaissance Capital’s profile of its 2018 share offering gives its founding year as 2003 and its headquarters as Malvern, the same town named on the company’s FDA filings from 2008 onward.

Its product is NeuroStar, a system for transcranial magnetic stimulation, or TMS. In the announcement of the companies’ 2024 merger, as published by the law firm Torys, Greenbrook TMS described TMS as providing local electromagnetic stimulation to specific brain regions associated with mood regulation. Neuronetics, in the same text, calls its therapy NeuroStar Advanced Therapy for Mental Health and describes it as “a non-drug, noninvasive treatment.”

The NeuroStar name does most of the public work. The company’s patient website is neurostar.com, which Renaissance Capital also lists as the company’s website, and the FDA’s device records carry NeuroStar in almost every product name, from the original NeuroStar TMS System to the NeuroStar Advanced Therapy System.

Cleared in 2008, widened in 2022 and 2024.

The FDA’s records trace NeuroStar’s path. The agency’s de novo database lists DEN070003, the NeuroStar TMS System, requested by Neuronetics of Malvern, received in May 2007 and decided on 7 October 2008; the de novo route is the one the FDA uses to classify a new kind of device, and the entry sits under the classification “transcranial magnetic stimulator.” The FDA marks it as a “post-NSE” de novo, the route then used after a 510(k) submission — here K061053 — had found a device not substantially equivalent to anything already on the market. A Model 1.1 followed through a 510(k) clearance on 16 December 2008.

Further clearances followed through the 2010s and 2020s. The FDA lists further NeuroStar clearances in April 2013, March 2014 and twice in 2016. In November 2020 it cleared NeuroStar Advanced Therapy, and versions 3.7 and 3.8 of the Advanced Therapy System were cleared in 2023. In May 2022 it cleared the system as an adjunct for adults with obsessive-compulsive disorder, followed in June 2023 by a clearance for an accessory listed as the OCD MT Cap, and in March 2024 as an adjunct for major depressive disorder in adolescents aged 15 to 21, according to the indication forms filed with those decisions. In the text attached to its December 2024 merger announcement, Neuronetics describes NeuroStar as indicated for depressive episodes in adults with major depressive disorder who did not achieve satisfactory improvement from previous antidepressant medication in the current episode.

The 510(k) summary filed in 2023 for the adolescent clearance describes what the system physically is: a computerised, electromechanical device that passes brief, high currents through an electromagnetic coil placed against the patient’s scalp, producing magnetic pulses that induce an electric field in the brain tissue beneath. Its basic configuration, the summary says, includes a mobile console, a treatment chair, a head support system and the TrakStar data-management software, along with disposable supplies. It adds that the adolescent change was limited to labelling, with components and operation identical to the earlier cleared system.

The FDA’s recall database records two actions on system components: a 2009 recall of the SenStar treatment link, since terminated, and an August 2026 recall of cables in a coil assembly that did not conform to product specifications.

Design and documentation.

Neuromodulation companies sell devices that most people will never see. Spinal cord stimulators, sacral nerve stimulators, hypoglossal nerve implants and brain-computer interfaces sit under the skin or inside the skull, so the companies that make them have to show something else: the scale of the device, the place it sits in the body, and the people it is meant for.

A few images recur across the category. Implants are often photographed held between fingertips or beside a coin or a key fob, to make their size legible. X-ray-style renders show thin leads running along a spine or curving toward a nerve, with the generator drawn as a small rounded shape. Patient pages tend to use calm portraits at home, on walks or with family, rather than hospital scenes.

Brain-computer interface start-ups lean in another direction: glowing renders of the brain, electrode arrays magnified many times over, and photographs of lab benches, engineers and surgical teams. Their audience includes investors and researchers as much as doctors, and the imagery often reads as a promise about the future rather than a product shot.

The category also has its own meeting places. Trade congresses such as the North American Neuromodulation Society (NANS) meeting, the International Neuromodulation Society (INS) congress and the Society for Neuroscience annual meeting are where companies show booths, posters and new hardware to clinicians and scientists. This guide sets out what can be checked about each company — founding, ownership, products and approvals as dated sources state them — and marks clearly what rests only on the company’s own word.

From device maker to clinic operator.

Neuronetics went public in June 2018: Renaissance Capital’s profile gives 27 June 2018 as the offering date, and the shares trade on the Nasdaq under the ticker STIM.

In 2024 it moved from selling systems into running treatment centres. In an all-stock deal on which Torys advised Greenbrook, Neuronetics agreed to acquire Greenbrook TMS, which described itself as a provider of TMS and of Spravato, an esketamine nasal spray, at treatment centres in the United States. Before closing, Torys noted, Greenbrook’s lender, Madryn Asset Management, converted the amounts it was owed under Greenbrook’s credit agreement and its interim funding into Greenbrook shares, which were then exchanged for Neuronetics stock. On 10 December 2024 the two companies announced completion: Neuronetics acquired all of Greenbrook’s shares through a court-approved plan of arrangement under Ontario’s Business Corporations Act, Greenbrook’s shares were removed from the OTCQB market, and the combined company continued as Neuronetics, Inc., trading as STIM, Torys reported. Greenbrook also applied to stop being a reporting issuer in Canada.

Torys summed up the purpose of the merger as creating “a vertically integrated organization capable of providing TMS therapy at scale.” For the brand, that means the NeuroStar name now appears both on the equipment Neuronetics sells and in clinics the group runs.

For a design guide, Neuronetics shows a company that leads with a product name rather than its own: NeuroStar is the name on the website patients find, while Neuronetics stands behind it. Compare BrainsWay, another maker of TMS systems, and Inspire Medical Systems, another US neurostimulation company that listed in 2018. For this guide we use a deep plum, a violet and a soft lavender grey with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Neuronetics’s identity on hand — save it to a board in the Made Good inspiration library.